Researchers reviewed the impact of prehabilitation on several surgery outcomes measures in patients with colorectal cancer.

Minimal residual disease negativity was achieved at a significantly higher rate with venetoclax-based therapies, supporting its role in CLL.

The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

HealthDay News — Children with congenital heart disease (CHD) have increased risk of developing cancer, according to a research letter published in the March 18 issue of Circulation.

According to investigators, there is no validated PSA-based endpoint to compare oncologic outcomes after radical prostatectomy and radiation therapy for localized prostate cancer.

Pediatric patients with ALL were found to experience deficits in their motor skills between at least 1 month and 4 years after completing treatment.

Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.

Researchers sought to determine whether using HRD sources for HSCT would be effective for pediatric patients with hematologic cancers compared with UCB sources.

The dose of paclitaxel used in the new approach was 16-fold lower than that typically used in free paclitaxel, but with similar efficacy.

HealthDay News — Adequate breastfeeding (BF) and avoidance of sugary beverages in early life may reduce the risk for preadolescent obesity in infants exposed to gestational diabetes (GDM), according ...

Using AI-enabled tools to automatically deny more and more needed care is not the reform of prior authorization physicians and patients are calling for,” said AMA President Bruce A. Scott, MD.

This is the first report on the long-term durability of response among complete responders to mitomycin C chemoablation of low-grade upper tract urothelial carcinoma.